ContraFect to Chair and Participate in Virtual Superbugs & Superdrugs 2020 Conference
March 30 2020 - 5:00AM
ContraFect Corporation (Nasdaq:CFRX), a clinical-stage
biotechnology company focused on the discovery and development of
direct lytic agents (DLAs), including lysins and amurin peptides,
as new medical modalities for the treatment of life-threatening,
antibiotic-resistant infections, today announced that Cara Cassino,
MD, Chief Medical Officer and Executive Vice President of Research,
will virtually chair the opening day of the 22nd Annual Superbugs
& Superdrugs 2020 Conference. Dr. Cassino will also virtually
present the Company’s anti-infective portfolio and platform
technology of DLAs in her talk, “Exploring Direct Lytic Agents
(DLAs) and their potential as a successful disruptive
anti-infective technology.”
Dr. Cassino will discuss the characteristics and
benefits of DLAs against drug-resistant pathogens, the clinical
performance of exebacase, and the ongoing Phase 3 DISRUPT (Direct
Lysis of Staph aureus Resistant Pathogen Trial) superiority design
study of exebacase in patients with Staph aureus bacteremia,
including right-sided endocarditis. In addition, she will also
highlight ContraFect’s broad-based Gram-negative discovery program,
which discovers, optimizes, and develops DLAs to specifically
target the world’s most resistant Gram-negative pathogens.
Presentation Details:
Presentation Title: Exploring Direct Lytic
Agents (DLAs) and their potential as a successful disruptive
anti-infective technologyTime and Date: Monday,
March 30, 2020, 11:30 a.m. GMT
Remote Access:
https://www.smi-online.co.uk/pharmaceuticals/uk/superbugs-superdrugs
About ContraFect
ContraFect is a biotechnology company focused on
discovering and developing differentiated biologic therapies for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our platform of DLAs, which
include lysins and amurin peptides. Lysins are a new class of DLAs
which are recombinantly produced antimicrobial proteins with a
novel mechanism of action associated with the rapid killing of
target bacteria, eradication of biofilms and synergy with
conventional antibiotics. Amurin peptides are a new class of DLAs,
which exhibit broad-spectrum activity against a wide range of
antibiotic-resistant Gram-negative pathogens, including Pseudomonas
aeruginosa (P. aeruginosa), Acinetobacter baumannii, and
Enterobacter species. We believe that the properties of our lysins
and amurin peptides will make them suitable for targeting
antibiotic-resistant organisms, such as methicillin-resistant Staph
aureus (MRSA) and P. aeruginosa, which can cause serious infections
such as bacteremia, pneumonia and osteomyelitis. We have completed
a Phase 2 clinical trial for the treatment of Staph aureus
bacteremia, including endocarditis, with our lead lysin candidate,
exebacase, which is the first lysin to enter clinical studies in
the U.S. Based on final data from the Phase 2 superiority trial,
the FDA has granted Breakthrough Therapy designation to exebacase
for the treatment of MRSA bloodstream infections (bacteremia),
including right-sided endocarditis, when used in addition to
standard-of-care (SOC) anti-staphylococcal antibiotics in adult
patients.
Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.
Forward-Looking Statements
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding ContraFect’s
ability to discover and develop DLAs as new medical modalities for
the treatment of life-threatening, antibiotic-resistant infections,
statements regarding the conference and ContraFect’s research and
development activities, ContraFect’s ability to address life
threatening infections using its DLA platform, whether lysins
are a new class of DLAs which are recombinantly produced,
antimicrobial proteins with a novel mechanism of action associated
with the rapid killing of target bacteria, eradication of biofilms
and synergy with conventional antibiotics, whether amurins exhibit
broad-spectrum activity against a wide range of
antibiotic-resistant Gram-negative pathogens, whether the
properties of ContraFect’s lysins and amurins will make them
suitable for targeting antibiotic-resistant organisms, such as MRSA
and P. aeruginosa and statements made regarding Breakthrough
Therapy. Forward-looking statements are statements that are not
historical facts, nor assurances of future performance. Instead,
they are based on ContraFect’s current beliefs, expectations and
assumptions regarding the future of its business, future plans,
strategies, projections, anticipated events and trends, the economy
and other future conditions. Because forward-looking statements
relate to the future, they are subject to inherent risks,
uncertainties and changes in circumstances that are difficult to
predict and many of which are beyond ContraFect’s control,
including those detailed under the caption “Risk Factors” in
ContraFect's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in
the forward-looking statements. Important factors that could cause
actual results to differ include, among others, our ability to
develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations Contacts
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Lauren StivalStern Investor RelationsTel: 212-362-1200Email:
lauren.stival@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024